Table 1. Provider and patient characteristics for the derivation and validation cohort and the adenoma detection rate per patient subgroup.
| Derivation cohort | Validation cohort | |||
|---|---|---|---|---|
| All patients [N = 9934] N (%)a |
Patients with ≥1 adenoma [N = 3568] N (ADR)a |
All patients [N = 10034] N (%)a |
Patients with ≥1 adenoma [N = 4013] N (ADR)a |
|
| Provider characteristics | ||||
| Centerb, median N (range) | 1544 (1144–3336) | 537 (431–1232) | 2492.5 (1228–3821) | 735 (561–1982) |
| Physicianc, median N (range) | 289 (55–725) | 93 (11–306) | 246 (57–812) | 96 (12–330) |
| Patient characteristics | ||||
| Age in years, mean ± SD | 60.2 ± 7.7 | 61.3 ± 7.8 | 61.0 ± 8.2 | 61.8 ± 8.3 |
| Female | 5209 (52.4) | 1542 (29.6) | 5237 (52.2) | 1826 (34.9) |
| Male | 4725 (47.6) | 2026 (42.9) | 4797 (47.8) | 2187 (45.6) |
| BMI in kg/m2, mean ± SD | 28.3 ± 5.6 [N = 6851]d |
28.8 ± 5.5 [N = 2538]d |
29.2 ± 5.8 [N = 6511]d |
29.7 ± 5.8 [N = 3120]d |
| ASA I | 2689 (27.1) | 793 (29.5) | 1920 (19.1) | 668 (34.8) |
| ASA II | 6455 (65.0) | 2420 (37.5) | 7532 (75.1) | 3119 (41.4) |
| ASA III or IVe | 790 (8.0) | 355 (44.9) | 582 (5.8) | 226 (38.8) |
| Race | ||||
| Otherf | 6368 (64.1) | 2250 (35.3) | 8306 (82.8) | 3463 (41.7) |
| African-American or black | 1320 (13.3) | 477 (36.1) | 701 (7.0) | 263 (37.5) |
| Asian | 134 (1.3) | 49 (36.6) | 149 (1.5) | 51 (34.2) |
| Unknown or patient declined to provide | 2112 (21.3) | 792 (37.5) | 878 (8.8) | 236 (26.9) |
| Ethnicity | ||||
| Not Hispanic or Latino | 5933 (59.7) | 2067 (34.8) | 8451 (84.2) | 3517 (41.6) |
| Hispanic or Latino | 1415 (14.2) | 533 (37.7) | 87 (0.9) | 31 (35.6) |
| Unknown or patient declined to provide | 2586 (26.0) | 968 (37.4) | 1496 (14.9) | 465 (31.1) |
| Indication for colonoscopyg | ||||
| Screening | 7353 (74.0) | 2409 (32.8) | 6518 (65.0) | 2361 (36.2) |
| Surveillance | 2581 (26.0) | 1159 (44.9) | 3516 (35.0) | 1652(47.0) |
| Risk assessmenth | ||||
| Average risk | 6558 (66.0) | 2168 (33.1) | 6589 (65.7) | 2452 (37.2) |
| High risk | 3376 (34.0) | 1400 (41.5) | 3445 (34.3) | 1561 (45.3) |
ADR, adenoma detection rate, i.e. proportion of patients with ≥1 adenoma detected per subgroup; ASA, American Society of Anesthesiology physical status class; BMI, body mass index; N, number of patients; SD, standard deviation.
aUnless, stated otherwise in the beginning of the row.
bFive centers were included in the derivation cohort, and four centers in the validation cohort.
cThirty-five physicians were included in the derivation cohort, and thirty-one physicians were included in the validation cohort.
dNumber of patients without missing values.
eOnly three patients in the development cohort and no patients in the validation cohort were in ASA category IV and therefore ASA III and IV were combined.
fIncluding white, native American, Alaska native, native Hawaiian, native Pacific patients and patient’s race categorized as other.
gThe indication is considered surveillance for patients with a personal history of colorectal adenomas or surveillance marked as indication on the GastroIntestinal Quality Improvement Consortium (GIQuIC) form.
hThe number of patients categorized per reason for high risk of adenoma detection are displayed in supporting information Table 1 (S1 Table).